As of September 30, 2026, Sarepta Therapeutics, Inc. carries a market capitalization of 1.73B, placing it among publicly traded companies globally. Its enterprise value stands at 1.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.73B |
| Enterprise Value | 1.88B |
Sarepta Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 3, 2027.
| Earnings Date | 3/3/2027 |
As of September 30, 2026, Sarepta Therapeutics, Inc. has 107.23M shares outstanding.
| Shares Outstanding | 107.23M |
As of September 30, 2026, Sarepta Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 130.48. The price-to-sales ratio is 0.98, and the price-to-book ratio stands at 1.28.
| PE Ratio | 130.48 |
| PS Ratio | 0.98 |
| PB Ratio | 1.28 |
| P/TBV Ratio | 1.31 |
| P/FCF Ratio | 11.64 |
| P/OCF Ratio | 10.38 |
These figures are as of September 30, 2026. The EV/Sales ratio of 1.09 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Sarepta Therapeutics, Inc. trades at an EV/FCF ratio of 10.37, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.88B versus a market cap of 1.73B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 1.09 |
| EV / FCF | 10.37 |
As of September 30, 2026, Sarepta Therapeutics, Inc. maintains a current ratio of 3.46, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 68.88, indicating elevated leverage, while an interest coverage ratio of -0.20 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.46 |
| Quick Ratio | 1.99 |
| Debt / Equity | 68.88 |
| Debt / EBITDA | -62.89 |
| Interest Coverage | -0.20 |
Over the twelve months ended September 30, 2026, Sarepta Therapeutics, Inc. posted a return on equity (ROE) of 1.04, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -0.75, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 0.44, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 1.89, useful for judging operating efficiency across full business cycles. The company generates approximately 2.07M in revenue per employee across its workforce of 835.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.87 indicates how many times Sarepta Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 1.04 |
| Return on Assets (ROA) | 0.44 |
| Return on Invested Capital (ROIC) | -0.75 |
| Return on Capital Employed (ROCE) | 1.89 |
| Revenue Per Employee | 2.07M |
| Employee Count | 835.00 |
| Inventory Turnover | 0.87 |
Over the twelve months ended September 30, 2026, Sarepta Therapeutics, Inc. recorded 19.94M in income tax expense. That works out to an effective tax rate of 60.49, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 32.97M, leaving 13.02M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 19.94M |
| Effective Tax Rate | 60.49 |
As of the close on November 17, 2026, Sarepta Therapeutics, Inc.'s stock has declined approximately 8.27% over the past 52 weeks. The 50-day moving average sits at 16.25, while the 200-day moving average is 16.00.
| 52-Week Price Change | -8.27% |
| 50-Day Moving Average | 16.25 |
| 200-Day Moving Average | 16.00 |
Over the twelve months ended September 30, 2026, Sarepta Therapeutics, Inc. generated 1.73B in revenue and converted that into 13.02M in net income, yielding earnings per share of 0.12. EBITDA reached -14.77M, while operating income came in at -7.41M.
| Revenue | 1.73B |
| Gross Profit | 980.21M |
| Operating Income | -7.41M |
| Pretax Income | 32.97M |
| Net Income | 13.02M |
| EBITDA | -14.77M |
| EBIT | -43.14M |
| Earnings Per Share (EPS) | 0.12 |
As of September 30, 2026, Sarepta Therapeutics, Inc. holds 775.34M in cash and equivalents against 929.09M in total debt, resulting in a net debt position of 339.34M. Total book value stands at 1.35B, with working capital of 1.43B providing operational flexibility.
| Cash & Cash Equivalents | 775.34M |
| Total Debt | 929.09M |
| Net Debt | 339.34M |
| Equity (Book Value) | 1.35B |
| Book Value Per Share | 12.58 |
| Working Capital | 1.43B |
Sarepta Therapeutics, Inc. produced 163.72M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -11.91M in capital expenditures, free cash flow totaled 151.81M - equivalent to 1.44 per share.
| Operating Cash Flow | 163.72M |
| Capital Expenditures | -11.91M |
| Free Cash Flow | 151.81M |
| FCF Per Share | 1.44 |
Over the twelve months ended September 30, 2026, Sarepta Therapeutics, Inc. posted a gross margin of 56.79, reflecting its pricing power and cost economics. The operating margin of -0.43 and net profit margin of 0.75 provide insight into operational efficiency.
| Gross Margin | 56.79 |
| Operating Margin | -0.43 |
| Pretax Margin | 1.91 |
| Profit Margin | 0.75 |
| EBITDA Margin | -0.86 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 8.59, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.99, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Sarepta Therapeutics, Inc. shareholders.
| Shareholder Yield | 1.99 |
| FCF Yield | 8.59 |
Sarepta Therapeutics, Inc.'s most recent stock split took place on July 12, 2012 with a 6:1 split ratio.
| Last Split Date | 7/12/2012 |
| Split Ratio | 6:1 |
As of September 30, 2026, Sarepta Therapeutics, Inc. has an Altman Z-Score of -0.09, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.09 |